Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma.
Jensen
R T
RT
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892.
Fraker
D L
DL
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001774:Blood Chemical Analysis / Q000379:methods; D003131:Combined Modality Therapy; D004379:Duodenal Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005753:Gastric Mucosa / Q000473:pathology; D015408:Gastrinoma / Q000175:diagnosis* / Q000378:metabolism / Q000556:secondary / Q000628:therapy; D005755:Gastrins / Q000032:analysis* / Q000097:blood / Q000378:metabolism; D006499:Hepatic Artery; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009377:Multiple Endocrine Neoplasia / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D010437:Peptic Ulcer / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D013157:Splenic Artery; D015043:Zollinger-Ellison Syndrome / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D005755:Gastrins; D064747:Lansoprazole; D007372:Interferons; D009853:Omeprazole